Gilead Sciences Inc - Company Profile
Powered by
All the data and insights you need on Gilead Sciences Inc in one report.
- Save hours of research time and resources with
our up-to-date Gilead Sciences Inc Strategy Report
- Understand Gilead Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreGilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. It markets its products through commercial teams, third-party distributors and corporate partners. Gilead's commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.
Gilead Sciences Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | - |
HIV/AIDS | AmBisome |
Atripla | Atripla |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, the company expanded its collaboration with Nurix Therapeutics to produce multiple additional clinical candidates. |
2024 | Acquisitions/Mergers/Takeovers | In March, the company acquired CymaBay Therapeutics for US$4.3 billion. |
2024 | Contracts/Agreements | In March, the company and Xilio Therapeutics entered into a license agreement to develop and market Xilio’s Phase 1 tumor-activated IL-12 program, XTX30. |
Competitor Comparison
Key Parameters | Gilead Sciences Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | Abbott Laboratories |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
City | Foster City | Kenilworth | New York | Basel | Abbott Park |
State/Province | California | New Jersey | New York | - | Illinois |
No. of Employees | 18,000 | 72,000 | 88,000 | 76,057 | 114,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Daniel P. O’Day | Chairman; Chief Executive Officer | Executive Board | 2019 | 59 |
Andrew Dickinson | Chief Financial Officer | Senior Management | 2016 | 54 |
Merdad V. Parsey, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2019 | 61 |
Johanna Mercier | Chief Commercial Officer | Senior Management | 2019 | 54 |
Flavius Martin, MD | Executive Vice President - Research | Senior Management | 2021 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward